Such effects have been observed in patients with rare MC4R pathway–associated diseases, such as LEPR deficiency, POMC deficiency, and BBS who have been treated with the MC4R agonist setmelanotide, which was additionally associated with rapid improvements in hunger. The gene discussed is POMC; the disease is Bardet-Biedl syndrome.